![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PARP16 |
Gene summary for PARP16 |
![]() |
Gene information | Species | Human | Gene symbol | PARP16 | Gene ID | 54956 |
Gene name | poly(ADP-ribose) polymerase family member 16 | |
Gene Alias | ARTD15 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q8N5Y8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54956 | PARP16 | HCC1_Meng | Human | Liver | HCC | 7.46e-07 | 1.20e-02 | 0.0246 |
54956 | PARP16 | HCC2 | Human | Liver | HCC | 1.49e-08 | 2.05e+00 | 0.5341 |
54956 | PARP16 | S014 | Human | Liver | HCC | 3.89e-04 | 1.18e-01 | 0.2254 |
54956 | PARP16 | S027 | Human | Liver | HCC | 1.23e-13 | 1.69e+00 | 0.2446 |
54956 | PARP16 | S028 | Human | Liver | HCC | 6.50e-21 | 3.08e+00 | 0.2503 |
54956 | PARP16 | S029 | Human | Liver | HCC | 1.43e-12 | 2.05e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
GO:003497612 | Liver | HCC | response to endoplasmic reticulum stress | 189/7958 | 256/18723 | 1.43e-24 | 4.06e-22 | 189 |
GO:003596612 | Liver | HCC | response to topologically incorrect protein | 123/7958 | 159/18723 | 2.60e-19 | 3.44e-17 | 123 |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:001908021 | Liver | HCC | viral gene expression | 77/7958 | 94/18723 | 4.33e-15 | 3.12e-13 | 77 |
GO:000698612 | Liver | HCC | response to unfolded protein | 103/7958 | 137/18723 | 6.50e-15 | 4.48e-13 | 103 |
GO:003596712 | Liver | HCC | cellular response to topologically incorrect protein | 89/7958 | 116/18723 | 5.61e-14 | 3.39e-12 | 89 |
GO:003462012 | Liver | HCC | cellular response to unfolded protein | 71/7958 | 96/18723 | 3.70e-10 | 1.22e-08 | 71 |
GO:003096811 | Liver | HCC | endoplasmic reticulum unfolded protein response | 56/7958 | 74/18723 | 6.47e-09 | 1.67e-07 | 56 |
GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
GO:001908211 | Liver | HCC | viral protein processing | 23/7958 | 29/18723 | 5.86e-05 | 5.38e-04 | 23 |
GO:007190021 | Liver | HCC | regulation of protein serine/threonine kinase activity | 189/7958 | 359/18723 | 5.97e-05 | 5.47e-04 | 189 |
GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
GO:0072525 | Liver | HCC | pyridine-containing compound biosynthetic process | 22/7958 | 32/18723 | 2.43e-03 | 1.18e-02 | 22 |
GO:0072524 | Liver | HCC | pyridine-containing compound metabolic process | 25/7958 | 38/18723 | 3.18e-03 | 1.47e-02 | 25 |
GO:0070213 | Liver | HCC | protein auto-ADP-ribosylation | 10/7958 | 12/18723 | 4.79e-03 | 2.02e-02 | 10 |
GO:003649811 | Liver | HCC | IRE1-mediated unfolded protein response | 14/7958 | 19/18723 | 5.94e-03 | 2.44e-02 | 14 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP16 | SNV | Missense_Mutation | rs371115400 | c.229N>T | p.Asp77Tyr | p.D77Y | Q8N5Y8 | protein_coding | deleterious(0.01) | benign(0.292) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | novel | c.941N>C | p.Phe314Ser | p.F314S | Q8N5Y8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
PARP16 | SNV | Missense_Mutation | rs143588412 | c.842C>T | p.Ser281Leu | p.S281L | Q8N5Y8 | protein_coding | tolerated(0.06) | benign(0.352) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | novel | c.622N>T | p.Ile208Phe | p.I208F | Q8N5Y8 | protein_coding | tolerated(0.12) | benign(0.006) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
PARP16 | SNV | Missense_Mutation | novel | c.239A>C | p.Lys80Thr | p.K80T | Q8N5Y8 | protein_coding | tolerated(0.4) | benign(0.029) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | novel | c.318N>T | p.Glu106Asp | p.E106D | Q8N5Y8 | protein_coding | tolerated(0.26) | benign(0.019) | TCGA-DD-AACF-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PARP16 | SNV | Missense_Mutation | c.278N>T | p.Lys93Met | p.K93M | Q8N5Y8 | protein_coding | deleterious(0) | possibly_damaging(0.698) | TCGA-50-5946-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
PARP16 | SNV | Missense_Mutation | rs756333312 | c.664N>C | p.Asp222His | p.D222H | Q8N5Y8 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-34-2600-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | novel | c.893T>A | p.Leu298Gln | p.L298Q | Q8N5Y8 | protein_coding | deleterious(0.02) | probably_damaging(0.976) | TCGA-G9-A9S7-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Unknown | Unknown | SD |
PARP16 | SNV | Missense_Mutation | c.341N>T | p.Ala114Val | p.A114V | Q8N5Y8 | protein_coding | tolerated(0.34) | benign(0.003) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |